Important notice: Alluvi has never operated any social media accounts. Any profile using the Alluvi name is a scam. Alluviretatrutide.uk is the only official Alluvi website.Important notice: Alluvi has never operated any social media accounts. Any profile using the Alluvi name is a scam. Alluviretatrutide.uk is the only official Alluvi website.Important notice: Alluvi has never operated any social media accounts. Any profile using the Alluvi name is a scam. Alluviretatrutide.uk is the only official Alluvi website.
ALLUVI

Home » Shop » Tirzepatide 40mg (R&D Only)

Tirzepatide 40mg (R&D Only)
← Back to Shop

Tirzepatide 40mg

R&D Only

£129.99

12-16 week supply
Tirzepatide formulation supplied in a pre-filled research device for controlled laboratory R&D applications.

Delivery: Dispatched with a cold pack.
  • 12-16 week research supply
  • Pre-filled research device
  • Sealed format for stability
  • Cold pack delivery
  • Produced for laboratory research only

Research & Development purposes only. Not for human or veterinary consumption.

Certificate of Analysis

Batch-tested quality assurance for research-grade material

Certificate of Analysis - Tirzepatide 40mg

Quality Assurance Report

ProductTirzepatide 40mg (R&D Only)
Batch NumberTZ-2403-B
Certificate IDTZ-2403-C5206
Test DateJune 2026
Purity (HPLC)PASS
Identity (ESI-MS)PASS
EndotoxinPASS
StatusAPPROVED FOR RESEARCH USE
Verification: This certificate applies to batch TZ-2403-B only. Each batch is independently tested using HPLC, ESI-MS, and USP methods.
Storage: -20°C. For research and development purposes only. Not for human or veterinary use.
Download Full Report (PDF)

Scientific References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity — SURMOUNT-1 Trial." N Engl J Med. 2022;387:205–216. PubMed
  2. Frías JP, Davies MJ, Rosenstock J, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes — SURPASS-2 Trial." Lancet. 2021;398(10295):583–598. PubMed
  3. Tirzepatide — Wikipedia. Encyclopedia entry covering pharmacology, clinical trial data (SURMOUNT, SURPASS), and regulatory information for this dual GIP/GLP-1 receptor agonist.

These references are provided for informational and research reference purposes. Alluvi does not claim that its products reproduce the results of cited studies. Products are supplied exclusively for controlled research and development purposes.